



OraSure Technologies Appoints New Chief Financial Officer

November 1, 2001

BETHLEHEM, Pa.--(BW HealthWire)--Nov. 1, 2001--OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the appointment of Ronald H. Spair to the position of Executive Vice President and Chief Financial Officer.

Mr. Spair joins OraSure Technologies with extensive senior financial experience in the pharmaceutical and biotechnology industries. Mr. Spair has held the position of Chief Financial Officer with several pharmaceutical or biotechnology companies - Delsys Pharmaceutical Corporation, Supergen, Inc., Sparta Pharmaceuticals, Inc., and Envirogen, Inc.

During this period, Mr. Spair had responsibility for directing finance, accounting, financial planning, treasury, human resources, risk management, and information technology matters at these companies. Mr. Spair has also had extensive experience negotiating mergers and acquisitions, development and licensing transactions, and corporate financings.

Mr. Spair is a Certified Public Accountant and received both his BS in Accounting and his MBA from Rider College.

"We are privileged to have Ron join OraSure Technologies," stated Robert D. Thompson, Chief Executive Officer. "He brings significant management and leadership experience relating to financial and strategic matters in our industry. Ron is an excellent fit for our Company and is an important addition to our management team."

Richard D. Hooper, who has held the position of Chief Financial Officer on an interim basis since the merger in September 2000, of Epitepe, Inc. and STC Technologies, Inc. into OraSure Technologies, will continue with the Company as Vice President, Finance.

About OraSure Technologies

OraSure Technologies, Inc. develops, manufactures and markets medical devices and diagnostic products for use by public- and private-sector clients, clinical laboratories, physicians' offices and workplace testing.

OraSure Technologies is the leading supplier of oral fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV. In addition, the Company supplies oral fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.

www.orasure.com

CONTACT: OraSure Technologies, Inc., Bethlehem

Shannon Morin, 610/882-1820

investorinfo@orasure.com